Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2637)

NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the 2026 first extraordinary general meeting (the "**2026 First EGM**") of Fujian Haixi Pharmaceuticals Co., Ltd. (the "**Company**") will be held at Conference Room, Floor 1, Block B, No. 177 Jinda Road, Jianxin Town, Cangshan District, Fuzhou, Fujian Province, the PRC on Tuesday, 4 August 2026 at 10:00 a.m. for the purpose of considering and, if thought fit, approving the following resolutions. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated 15 July 2026 (the "**Circular**").

ORDINARY RESOLUTIONS

1. Proposed Change of External Auditor, and to authorize the Board to fix the remuneration.

2. Proposed appointment of executive Director.

By order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Kang Xinshan
Executive Director, Chairman and General Manager

Hong Kong, 15 July 2026

As of the date of this notice, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Mr. Li Junqing as executive Directors; (ii) Mr. Wang Xinkun and Mr. Xu Dong as non-executive Directors; and (iii) Ms. Wang Shan Shan, Ms. Pu Meiting and Mr. Lin Bin as independent non-executive Directors.

Notes:

1. For further details of the resolutions, please refer to the circular of the Company dated 15 July 2026.

2. All resolutions at the 2026 First EGM will be taken by poll pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The poll results will be published on the website of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") at www.hkexnews.hk and the Company's website at https://www.hxpharma.com in accordance with the Listing Rules.

3. All Shareholders are eligible for attending the 2026 First EGM. Any Shareholder of the Company entitled to attend and vote at the 2026 First EGM convened by the above notice is entitled to appoint a proxy or more than one proxy to attend the 2026 First EGM and vote instead of him/her. A proxy need not be a Shareholder. If more than one proxy is appointed, the number of Shares in respect of which each such proxy so appointed must be specified in the relevant proxy form. Every Shareholder present in person or by proxy shall be entitled to one vote for each Share held by him/her.

4. In order to be valid, the proxy form together with the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy thereof, must be completed and returned to the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for H Shareholders) not less than 24 hours before the time appointed for the 2026 First EGM. Completion and return of the proxy form will not preclude a Shareholder from attending and voting at the 2026 First EGM or any adjourned meeting thereof should he/she so wish.

5. For the purpose of determining the Shareholders' eligibility to attend and vote at the 2026 First EGM (or any adjourned meeting thereof), the register of members of the Company will be closed from Thursday, 30 July 2026 to Tuesday, 4 August 2026, both days inclusive, during which period no transfer of Shares will be registered. The record date will be Tuesday, 4 August 2026. In order for the H Shareholders to qualify for attending and voting at the 2026 First EGM, all properly completed share transfer forms together with the relevant H share certificates shall be lodged with the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Wednesday, 29 July 2026.

6. The 2026 First EGM is expected to take no more than half a day. Shareholders who attend the 2026 First EGM (in person or by proxy) shall bear their own travelling and accommodation expenses.

7. Shareholders who are entitled to attend and vote at the 2026 First EGM may appoint one or more proxies to attend and vote on their behalf. A proxy need not be a Shareholder.

8. Shareholders or their proxies shall provide their identification documents when attending the 2026 First EGM. In case of a corporate Shareholder, its proxy or other person authorized to attend the meeting with a resolution passed by the board of directors or other decision-making authorities of such corporate Shareholder, should provide a copy of such resolution.

9. In case of joint holders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s) and for this purpose seniority will be determined by the order in which the names stand on the register of members of the Company in respect of the joint shareholding.

10. The contact of the Company:

Address: Fujian Haixi Pharmaceuticals Co., Ltd.
Floor 3&4, Block B, No. 177 Jinda Road
Jianxin Town, Cangshan District
Fuzhou, Fujian Province
the PRC

Postal Code: 350028

Contact Person: Zhang Junhuan (張俊環)

Email: junhuan.zhang@hxpharma.com